"The revised Drug Act is very good news for people with pain in India," said Diederik Lohman, senior health researcher at Human Rights Watch. "These changes will help spare millions of people the indignity of suffering needlessly from severe pain."
The amendments to the Narcotic Drugs and Psychotropic Substances Act (the Drug Act) eliminate archaic rules that obligated hospitals and pharmacies to obtain four or five licenses, each from a different government agency, every time they wanted to purchase strong pain-killing medicines, HRW said.
In the seven years following the introduction of the Drug Act in 1985, morphine use in India had plummeted by 97 percent due to these complications, adding to the suffering of the patients.
HRW had estimated the quantity of morphine India used in 2008 was sufficient for just four percent of patients with advanced cancer who required it.
The Rajya Sabha approved the amendments yesterday. The Lok Sabha had passed them a day earlier.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
